Overview

Gut Microbiota Medium (GMM) is the mucin-supplemented broth described by Goodman et al. (2011) Proceedings of the National Academy of Sciences 108:6252, specifically formulated to recover the maximum-diversity culturable fraction of the human gut microbiota — particularly the mucin-degrading members of the gut community that conventional media (BHI, YCFA, mGAM) cultivate poorly. The flagship organism is Akkermansia muciniphila ATCC BAA-835 (= DSM 22959), the verrucomicrobial mucin-degrader implicated in metabolic-health phenotypes (Plovier et al. 2017 Nat Med).

The defining ingredient is porcine gastric mucin (Type II or Type III, 4 g/L) — a complex glycoprotein that no other commercial culture medium currently supplies. The mucin provides both a fermentable substrate for mucin-degrading organisms (A. muciniphila, Bacteroides thetaiotaomicron mucin-utilisation locus, Ruminococcus torques, R. gnavus reclassified Mediterraneibacter gnavus) and host-glycan signal that primes expression of polysaccharide-utilisation loci. The medium also includes SCFA (acetate 33 mM, propionate 9 mM, isobutyrate / isovalerate / valerate 1 mM each — added post-autoclave inside the AAE), which support cross-feeding of SCFA-utilising Firmicutes. Because no commercially-validated ready-to-rehydrate GMM exists, this product addresses a clear market gap and complements the GMExpression YCFA platform for full-coverage human gut culturomics.

We also have

YCFA Modified Medium · YCFA Full Recipe · YCFA Base · Modified Chopped Meat Broth (ATCC 1490) · Chopped Meat with Carbohydrates · Beef Granules

Package Contents

Each GMExpression GMM kit contains:

  • Mixture A — pre-weighed GMM base (BHI base 18 g/L + Yeast extract 5 g/L + Trypticase 5 g/L + Glucose 2 g/L + Cellobiose 1 g/L + Maltose 1 g/L + Soluble starch 1 g/L + K2HPO4 + KH2PO4 + NaCl + MgSO4 + CaCl2 + resazurin) for 5 L final volume.
  • Mixture B — Porcine gastric mucin (Type II)  + L-cysteine·HCl, pre-blended, with Oxygen absorber. Default provided Porcine gastric mucin is Type II, end user can source Type III from Sigma if needed.
  • Stock H — Hemin stock, 1.00 mg/mL in 0.05 M NaOH. Packed in PET square bottle sealed in an aluminium-foil pouch. Dose 5.00 mL per litre, added with Mixture A before sterilisation.
  • Stock K — Vitamin K1, supplied in requested formats. Format A: 0.50 mg/mL in 95 % ethanol, 0.22 µm filter-sterilised, 15 mL, PET square bottle sealed in an aluminium-foil pouch. Format B: 5x 2 mL microtubes, each holding approximately 2 mg of pure vitamin K1, from which the user prepares a 0.50 mg/mL ethanolic stock. Dose 2.00 mL per litre in either format.
  • Stock S — branched and C5 short-chain fatty acids — iso-butyric, iso-valeric and n-valeric acid at 200 mmol/L each in water, PP bottle sealed. Dose 5.00 mL per litre, added with Mixture A at the dissolving step. Acetate and propionate are not in this bottle: these two items are supplied as sodium acetate and sodium propionate within Mixture A.
  • 5 × airtight PP storage bags + 5 × heat-resistant rubber bands.
  • Instruction manual.

Customisation options on request: agar variant at 15 g/L for plates; HMO-supplemented variant for infant-gut culturomics; a porcine-free variant substituting bovine submaxillary mucin (Sigma M3895); supply as PRAS Hungate tubes pre-poured ready for direct inoculation. Each is a separately specified formulation with its own recipe, process qualification and release criteria; contact technical support to confirm availability and lead time.

Composition — per 1 L equivalent unless stated otherwise

GMM broth base (per 1 L of the final media liquid)

ComponentConcentrationFunction
Brain Heart Infusion base (dehydrated)18.0 gRich peptone, glucose, infusion solids base
Yeast extract5.0 gB-vitamins, NAD precursors
Trypticase (pancreatic digest of casein)5.0 gSupplementary peptide source
D-Glucose2.0 gPrimary carbohydrate
Cellobiose1.0 gDisaccharide; supports Ruminococcus, Bacteroides
Maltose1.0 gDisaccharide; supports glucose-derived utilisation
Soluble starch1.0 gPolysaccharide; supports starch-utilising organisms
Sodium acetate, anhydrous2.707 gAcetate to 33 mmol/L; supplied as the salt within Mixture A
Sodium propionate, anhydrous0.865 gPropionate to 9 mmol/L; supplied as the salt within Mixture A
Porcine gastric mucin (Type II / III)4.0 gPrincipal glycan substrate — the component that distinguishes this medium; supports Akkermansia muciniphila and other mucin-degrading commensals and provides a defined mucin background for glycan-utilisation work
L-Cysteine·HCl0.5 gReducing agent; lowers the redox potential of the finished medium
Hemin (CAS 16009-13-5)5.0 mgRequired by Bacteroides; supplied as Stock H and added before sterilisation
Vitamin K1, phylloquinone  (CAS 84-80-0)1.0 mgLLipophilic naphthoquinone growth factor for Bacteroides, Porphyromonas and Prevotella; supplied as Stock K and added after sterilisation
K2HPO4 / KH2PO42.0 g / 1.0 gPhosphate buffer
NaCl, MgSO4, CaCl22.0 g / 0.2 g / 0.05 gMineral mix
Resazurin1.0 mgRedox indicator (pink/red oxidised, colourless reduced)

Mixture A supplies the base above, including the two short-chain fatty acid salts, and totals 41.823 g per litre of finished medium. Five litres require 209.113 g and the bottle is filled to 215 g, a dispensing margin rather than an extra dose: weigh 41.823 g for every litre and do not divide the bottle by eye. Mucin and L-cysteine·HCl·H2O are supplied pre-blended as Mixture B; hemin and vitamin K1 are supplied as Stocks H and K. Salt masses are declared on the anhydrous basis; the controlled formula specifies the hydrate actually supplied and the equivalent hydrated mass used at weighing. The brain-heart-infusion base is a formulated product that carries its own carbohydrate, phosphate and salt content, so the figures above are declared addition amounts rather than total analysed concentrations.

Short-chain fatty acid supplement (Stock S; final concentrations in the finished media liquid)

Short-chain fatty acidFinal concentrationNotes
Acetate33 mM (2.7 g/L as anhydrous sodium acetate)Principal colonic SCFA; carbon and energy source for acetate-utilising taxa
Propionate9 mM (0.87 g/L as anhydrous sodium propionate)Secondary most abundant colonic SCFA; a fermentation end-product of Bacteroides and Akkermansia
Iso-butyrate1 mM (0.09 g/L equiv)Branched-chain C4 acid
Iso-valerate1 mM (0.10 g/L equiv)Branched-chain C5 acid
n-Valerate1 mM (0.10 g/L equiv)Straight-chain C5 acid

Molar concentrations are the controlling specification; the mass equivalents are given on the declared chemical basis, and the acid or salt form actually supplied is stated on the lot dosing card. All five acids are present before sterilisation — acetate and propionate as their sodium salts within Mixture A, and the three branched and C5 acids as Stock S — so these are the concentrations present in the medium as autoclaved.

Adjust to pH 7.2 ± 0.2 at 25 °C once every component including Stock S is present and before the volume is made up. Release specification for the sterilised, reduced medium is pH 6.8–7.2 at 25 °C. Measure at the stated temperature: reading a warm preparation against a 25 °C specification is not reproducible, and automatic temperature compensation corrects the electrode response rather than the chemistry.

→Culturomics and Media Navigator

Need help matching this medium to your microorganism — or starting from a target organism and finding the medium that fits? Use the GMExpression Culturomics and Media Navigator: a curated, cross-referenced tool that lets you (i) start from a medium and view the bacterial taxa it is recommended for, or (ii) start from a target organism (genus, species, or DSMZ/ATCC strain ID) and view the panel of GMExpression media that will support it. The Navigator integrates Gut Microbiota Medium with the wider YCFA, Chopped Meat Broth, BHI-S, Wilkins-Chalgren, Modified GAM, Anaerobic Columbia Blood Agar, M2GSC, BBE, KVLB, CCFA, TPY, and Egg Yolk Agar catalogue.

Use and Applications

  • Culture-collection work on the human gut microbiota. A rich, mucin-containing broth for building isolate collections from stool and colonic mucosa, used alongside complementary media rather than as a single-medium strategy.
  • Enrichment and routine propagation of Akkermansia muciniphila (ATCC BAA-835 / DSM 22959) and other mucin-degrading commensals in research settings.
  • Mucin-degradation phenotyping. On the agar variant, isolates can be screened for zones of mucin clearing. Clearing is a phenotype, not an identification: confirm identity by an appropriate molecular or biochemical method.
  • Growth studies against a defined SCFA background. The medium is supplied with acetate, propionate and the three minor acids at fixed concentrations, giving a reproducible starting metabolite background for studies of butyrate producers and other acid-utilising taxa. Demonstrating cross-feeding as such additionally requires a donor–recipient design with the corresponding controls.
  • Glycan-utilisation research. Mucin provides a complex host-type glycan source for studies of polysaccharide-utilisation systems in Bacteroides thetaiotaomicron and related organisms. Induction of a specific locus is a testable question in this medium, measured directly, rather than a property conferred by the medium.
  • Isolation of gut commensals for defined-community work, including the assembly of isolate panels for gnotobiotic colonisation studies.
  • Research-stage process and consortium development in stool-bank and microbial-consortium programmes. Supplied for research use; it is not a diagnostic medium and does not carry clinical, FMT-release or live-biotherapeutic manufacturing qualification.

Compatible Microorganisms

The taxa below are supported by the composition of this medium and are listed as candidates for evaluation in your own workflow. Growth of a given strain depends on inoculum history, gas phase, incubation and transfer technique as well as on the medium, so qualify the strains you intend to work with against a strain-appropriate positive control.

Mucin-degraders (the GMM signature group)

  • Akkermansia muciniphila (ATCC BAA-835 = DSM 22959) — verrucomicrobial intestinal-mucin specialist. Mucin supplementation markedly improves its recovery and growth; culture-collection records also list mucin-free cultivation options for the type strain, so mucin is best described as the preferred substrate rather than an absolute requirement.
  • Bacteroides thetaiotaomicron (ATCC 29148) — extensive mucin-utilisation locus repertoire
  • Mediterraneibacter gnavus (formerly Ruminococcus gnavus; reclassified Togo et al. 2018 / Lawson et al. 2023)
  • Mediterraneibacter torques (formerly Ruminococcus torques) — mucin-degrading commensal
  • Bifidobacterium bifidum — extracellular endo-β-galactosidases acting on mucin glycans

Butyrate-producing commensals

  • Faecalibacterium duncaniae (DSM 17677 = A2-165; formerly assigned to F. prausnitzii) — acetate utilisation for butyrate production
  • Roseburia intestinalis (DSM 14610)
  • Agathobacter rectalis (formerly Eubacterium rectale; reclassified Rosero et al. 2016)
  • Anaerobutyricum hallii (formerly Eubacterium hallii; reclassified Shetty et al. 2018)
  • Anaerostipes caccae, A. hadrus

General gut commensals

  • Bacteroides fragilis, B. uniformis, B. ovatus, B. caccae; Phocaeicola vulgatus (formerly Bacteroides vulgatus)
  • Parabacteroides spp.
  • Bifidobacterium spp. (TPY preferred for selective Bifidobacterium isolation)
  • Lactobacillus sensu lato (per Zheng et al. 2020 reclassification)
  • Eubacterium limosum
  • Christensenella minuta (DSM 22607)
  • Coprococcus catus, C. eutactus

Preparation

1Weigh Mixture A. Use the pre-weighed Mixture A, 41.823 g per litre of finished medium, together with 5.00 mL of Stock S and 5.00 mL of Stock H per litre. Handle Stock S in a fume hood. Tare a clean autoclavable borosilicate bottle of at least 1.5× the final volume.
2Suspend and dissolve. Add Mixture A, Stock S and Stock H to approximately 900 mL of double distilled or MQ water per litre of finished medium. Heat with frequent agitation until the base is fully dissolved, following the dissolution guidance for the brain-heart-infusion base in use. Heat is for dispersion and deoxygenation; avoid thermal exposure beyond what dissolution requires.
3Add Mixture B (mucin + cysteine). Cool to approximately 80 °C. Add 4.5g of Mixture B to the medium as a dry powder under a gentle inert-gas stream, or pre-suspend it in a small volume of deoxygenated water and add that suspension. Stir until uniformly dispersed, using sufficient agitation to disperse the mucin without drawing air into the bulk or generating foam. A hazy, opalescent appearance is the expected endpoint; mucin does not give an optically clear solution.
4Adjust pH and make to the pre-sterilisation volume. Adjust to pH 7.2 ± 0.2 at 25 °C with 1 M NaOH or 1 M HCl, adding acid dropwise into the vortex of a stirred vessel so that the mucin is not locally precipitated. Then make up to 998 mL per litre of finished medium, leaving room for Stock K. Record the pH immediately before sterilisation.
5Dispense. Broth tubes: 5–10 mL per Hungate or screw-cap tube. Observe the fill limit and headspace allowance specified for the vessel and closure in use, so that liquid expansion during the cycle is accommodated.
6Sterilise. 121 °C for 15 min at approximately 103 kPa gauge, on a liquid cycle with slow exhaust. Qualify exposure time for the actual load and fill volume rather than assuming a single figure covers every batch. Use vented or loosened closures for conventional bottles; sealed anaerobic vessels require a closure arrangement and cycle validated for pressurised liquid sterilisation. Some hydrolysis of the mucin occurs during sterilisation. Where intact glycan structure is itself the experimental endpoint, characterise the mucin after processing.
7Add vitamin K1 to the sterilised medium. Once the vessels have cooled to 50 °C or below, add Stock K. Into each autoclaved Hungate tube, inject it through the rubber stopper with a 1.0 mL ultra-fine syringe — the syringe listed in section 2.1 of the instruction manual — at 2.0 µL per mL of broth, which is 20 µL for a 9.98 mL fill. Wipe the stopper with 70 % alcohol and let it dry, point the needle up and expel all air before injecting, inject slowly, and do not vent the tube or lift the stopper. Invert the tube gently two or three times to mix. For medium held in bulk, add 2.00 mL of Stock K per litre and mix. The running volume closes at 1.000 L: 998 + 2.00. Hemin is already present, having gone in before sterilisation. Holding it back for a post-sterilisation addition is permissible but adds a second aseptic transfer into a sterilised medium, and is not preferred; if it is done, add hemin first, mix thoroughly, and only then add vitamin K1 — never from one syringe, because Stock H is made up in 0.05 M sodium hydroxide and vitamin K1 is degraded by alkali hydroxides.
8Equilibrate and reduce. Transfer to the anaerobic workstation and allow the medium to equilibrate with the chamber atmosphere. Deoxygenation occurs through the liquid surface and the headspace, so a container that is sealed against gas exchange will not equilibrate merely by standing in the chamber: loosen closures, or use a vessel and gassing arrangement designed for the purpose. Confirm readiness by the resazurin indicator becoming colourless and by the reduction criteria set in the site method, rather than by elapsed time alone.
9Confirm the release pH. Verify the sterilised, reduced medium at pH 6.8–7.2 at 25 °C, measured under the gas phase of use. Investigate a result outside either limit. Any correction after sterilisation must use a validated sterile anaerobic addition, and the added volume must be recorded against the final volume.

Critical control points

  • Mucin source and grade. Sigma M2378 (Type II) is a crude preparation and M1778 (Type III) is partially purified; they differ in bound sialic acid and in non-mucin content. Bovine submaxillary and ovine intestinal mucins are different materials again. Treat each source and grade as a controlled formulation variant, fix one in the batch record, and revalidate any growth or glycan endpoint on a change.
  • SCFA addition stage. Stock S is added with Mixture A at the dissolving step, before sterilisation, and acetate and propionate are supplied as their sodium salts within Mixture A. At the working pH of this medium the five acids are present almost entirely as their non-volatile carboxylate anions — at pH 7.2 an acid of pKa 4.76 is about 0.4 % undissociated — and their salts are thermally stable well above 121 °C. This is the same stage at which the volatile fatty acid blend is incorporated in the standard YCFA preparations (DSMZ medium 1611, JCM medium 1130). Post-sterilisation addition from a separately sterilised stock remains a legitimate alternative where independent metabolite dosing is the object of the study; it requires a validated sterilisation route for the stock, an aseptic anaerobic transfer, and the added volume to be carried into the final-volume accounting.
  • Vitamin K1 dose and light protection. Stock K is 0.50 mg/mL, so the dose is 2.00 mL per litre — 10.0 mL for a 5 L batch, delivering 1.0 mg/L. Vitamin K1 decomposes in light: keep the bottle in its foil pouch, return it after each withdrawal, and switch off any glove-box UV lamp before bringing the stock or supplemented medium into the cabinet.
  • Final-volume convention. The medium is made up to 998 mL per litre before sterilisation, and Stock K brings it to 1.000 L afterwards. Every declared concentration refers to that final volume. Any further addition dilutes all of them and must be accounted for.
  • Reduction check. The resazurin indicator is a qualitative guide: colourless is consistent with a reduced medium, but it does not read out a specific redox potential, demonstrate sterility, or confirm that a given strain’s requirements are met. Use the site criteria for release, with a biological or instrumental control where the endpoint demands one.

Cautions

Mucin haze is expected. Prepared GMM is hazy to opalescent because the mucin is dispersed rather than truly dissolved. Compare each batch against a qualified reference appearance; an unusually clear or unusually heavy preparation is a prompt to check the Mixture B addition, the mucin lot and the heating history, not a diagnosis in itself.
Porcine biosecurity. Porcine gastric mucin is a porcine-derived component. EU, Japan, Canada, and other regions may apply zoosanitary checks. Sigma Type II / III mucin is produced from food-grade porcine stomach with TSE-equivalent safeguards; documentation pack on request.
Bovine components. The brain-heart-infusion base in Mixture A contains bovine infusion solids. Origin, traceability and the applicable import documentation are confirmed per lot; request the current documentation pack for the lot supplied when a specific certification is required for your jurisdiction.
Sealed containers under heat. Sterilise in vessels and closures approved for the cycle in use. A conventional bottle must be vented or its closure loosened; sealed anaerobic vessels are pressure-bearing and need a specifically validated closure and cycle. Do not improvise a seal to limit evaporation.
Porcine-free alternative. Bovine submaxillary mucin (Sigma M3895) is available as a custom-order substitution for facilities that exclude porcine material. It is animal-derived, as is the brain-heart-infusion base and the casein digest, so this variant is porcine-free rather than animal-component-free, and it is not a chemically defined medium. Mucin source affects glycan composition, so validate growth and any glycan-dependent endpoint on the variant you intend to use.
Handling Stock S. The concentrate is strongly odorous and the odour carries at very low concentrations; open and dispense it with adequate ventilation and avoid generating aerosol. Follow the storage and in-use period given on the lot dosing card. Free short-chain acids are irritant in concentrated form, so handle the undiluted stock with gloves and eye protection.
Mucin batch variability. Mucin is a complex biological material and varies between lots in glycosylation and protein-to-carbohydrate ratio. Qualify each prepared batch against a growth-promotion test using a nominated reference strain, an incubated uninoculated blank of the same medium, and acceptance limits established for your own inoculum, incubation and reading method. Mucin itself scatters light, so an optical-density endpoint is only meaningful when blanked against the matrix and shown to track viable growth.

Storage and Expiry · Safety

  • Dehydrated Mixture A: 15–30 °C in the original packaging, kept dry and closed.
  • Mixture B (mucin + cysteine, N2-flushed): 2–8 °C in the original sealed packaging. Mucin is hygroscopic and cysteine oxidises on exposure to air, so reseal promptly and keep the opened-bag interval short.
  • Stock H and Stock K: 2–8 °C, protected from light. Hemin in alkaline solution and vitamin K1 in ethanol are both light-sensitive.
  • Stock S: 15–25 °C is preferred. 2–8 °C is acceptable. Do not freeze. Keep tightly sealed in the PP bottle. Confirm the liquid is clear and in a single layer before every dose — see FAQ 5.
  • Prepared medium: store under the gas condition it will be used in. Medium held aerobically must be re-reduced before use with strict anaerobes.
  • Expiry. Each component and the prepared medium carry a dated expiry on the lot documentation, established against defined sterility, pH, redox and growth-promotion endpoints. Provisional periods are assigned pending completion of real-time stability studies, and the lot documentation is the governing statement.

Safety notes. Contains porcine and bovine biological components. Mucin powder is a respiratory irritant: weigh and transfer Mixture B in a fume hood, a ducted powder-weighing enclosure, or a biological safety cabinet. A laminar-flow clean bench is not suitable, because it directs filtered air outward across the work surface and protects the product rather than the operator. Dispense Stock S with adequate ventilation. Safety Data Sheets are supplied with the product.

References

  1. Goodman AL, Kallstrom G, Faith JJ, Reyes A, Moore A, Dantas G, Gordon JI. (2011). Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. PNAS 108(15): 6252–6257. doi: 10.1073/pnas.1102938108. [Origin of the gut-microbiota-medium approach to culture-collection work]
  2. Leibniz Institute DSMZ. Medium 1611: modified YCFA medium. [Fatty acids are incorporated before autoclaving; the vitamin solution is filter-sterilised separately]
  3. RIKEN BioResource Center JCM. Medium 1130: YCFA medium. [The neutralised volatile fatty acid mixture is included in the base before sterilisation]
  4. Leibniz Institute DSMZ. Cultivation of anaerobes — technical guidance on oxygen exclusion, redox indicators, gas-phase and buffer selection.
  5. Sakamoto M, Sakurai N, Tanno H, Iino T, Ohkuma M, Endo A. (2022). Genome-based, phenotypic and chemotaxonomic classification of Faecalibacterium strains: proposal of three novel species Faecalibacterium duncaniae sp. nov., Faecalibacterium hattorii sp. nov. and Faecalibacterium gallinarum sp. nov. IJSEM 72(5): 005379. doi: 10.1099/ijsem.0.005379. [Current identity of strain A2-165 = DSM 17677]
  6. Plovier H et al. (2017). A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine 23(1): 107–113.
  7. Derrien M, Vaughan EE, Plugge CM, de Vos WM. (2004). Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. IJSEM 54: 1469–1476.
  8. Browne HP et al. (2016). Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation. Nature 533: 543–546.
  9. Lagier J-C et al. (2016). Culture of previously uncultured members of the human gut microbiota by culturomics. Nature Microbiology 1: 16203.
  10. Rosero JA et al. (2016). Reclassification of Eubacterium rectale in the genus Agathobacter. IJSEM 66: 768–773.
  11. Shetty SA, Zuffa S, Bui TPN, Aalvink S, Smidt H, de Vos WM. (2018). Reclassification of Eubacterium hallii as Anaerobutyricum hallii. IJSEM 68: 3741–3746.
  12. Sigma-Aldrich product specifications: mucin from porcine stomach Type II (M2378, crude) and Type III (M1778, partially purified); bovine submaxillary mucin Type I-S (M3895).
  13. Duncan SH, Hold GL, Harmsen HJM, Stewart CS, Flint HJ. (2002). Growth requirements and fermentation products of Fusobacterium prausnitzii. IJSEM 52: 2141–2146.

Frequently Asked Questions

Q1. Why use GMM instead of YCFA for gut culturomics?
YCFA and GMM are complementary. YCFA is optimised for SCFA-utilising butyrate producers (Faecalibacterium, Roseburia) and gives excellent recovery of the Firmicutes-dominant fraction. GMM is optimised for mucin-utilising organisms (Akkermansia muciniphila, Bacteroides thetaiotaomicron, Mediterraneibacter gnavus) that YCFA does not recover well. For broad culture-collection work from human stool, run both media in parallel: they select for overlapping but distinct parts of the community, and the combined isolate set is larger than either medium returns alone. The recovery actually achieved depends on the donor, sample handling, culture format and incubation, so treat published recovery figures as specific to the study that produced them.
Q2. Why buy this as a kit rather than prepare it from individual ingredients?
Preparing a mucin-supplemented gut medium from scratch means sourcing and weighing more than a dozen components, including porcine gastric mucin and a five-component short-chain fatty acid blend, and reproducing that weighing accurately on every occasion. The kit supplies the base as a single pre-weighed blend, the mucin and cysteine pre-blended under nitrogen, and the hemin, vitamin K1 and SCFA concentrates as lot-documented stocks with a dosing card. The intent is batch-to-batch consistency and fewer weighing steps in the laboratory; it does not replace your own qualification of the medium for your application.
Q3. Can I omit the mucin to use GMM as a generic anaerobe medium?
Not by simply leaving out Mixture B. Mucin and L-cysteine·HCl are supplied pre-blended, so omitting the bag removes the reducing agent as well as the glycan substrate, and the result is neither a mucin-free GMM nor an adequately reduced medium. If you want a generic rich gut-anaerobe broth, use YCFA Modified (GMNB-YCFA02) or BHI-S (GMNB-BHIS01), which are formulated and priced for that purpose. A mucin-free variant of this formulation, with its own specified reducing system, is available as a custom order.
Q4. At what stage are the short-chain fatty acids added?
Stock S goes into the base at the dissolving step, with Mixture A and the hemin stock, and the medium is autoclaved with the five acids already in it. Stock K, that is vitamin K1, is added post-autoclave, once the broth has cooled to 50 °C or below. The chemistry supports carrying the acids through the autoclave. The boiling points quoted for short-chain acids belong to the pure, undissociated acids; in this medium the acids are buffered near neutrality, where they exist almost entirely as their sodium carboxylate salts. At pH 7.2 an acid of pKa 4.76 is roughly 0.4 % undissociated, and carboxylate salts are thermally stable far above 121 °C, so neither appreciable evaporation nor decomposition is expected on a standard liquid cycle. The same logic is applied in the standard YCFA preparations, which incorporate their volatile fatty acid blend before autoclaving. Adding the acids early also keeps the preparation simpler: the acids need no aseptic transfer of their own, and no oxygen enters with them after the cycle. The make-up volume accounts for the one post-sterilisation addition that does follow — the medium is made to 998 mL per litre and Stock K brings it to 1.000 L. Adding the stock after sterilisation remains a legitimate option where the study calls for independent metabolite dosing; it then needs a validated sterile stock, an aseptic anaerobic transfer, and the added volume carried into the final-volume calculation.
Q5. Can Stock S be refrigerated? Why must check before each dose?
Yes — 2–8 °C is permitted, though 15–25 °C is preferred, and it must never be frozen. The check matters more than the temperature. Stock S is a 200-fold concentrate of three free short-chain fatty acids in water, and water dissolves only so much of them: the two C5 acids, iso-valeric and n-valeric, already sit at roughly 50–85 % of that limit at room temperature, and solubility falls as the temperature falls. If they come out of solution they do not crystallise — all three acids melt below −29 °C — they separate as an oily, acid-rich second phase, seen as a faint haze in the bulk liquid or as droplets on the glass and around the neck. A dose drawn from a bottle in that state is not representative and under-delivers all three acids. So before every dose, bring the bottle to 15–25 °C, invert it 3–5 times and confirm a single clear phase. Never try to clarify a hazy bottle by filtration: filtering removes acid, not contaminant, and silently lowers the delivered dose. Keep the cap tight between uses, since the acids are volatile and evaporative loss concentrates what is left.
Q6. Can I substitute porcine mucin with another mucin source?
The standard formulation uses porcine gastric mucin, either Sigma M2378 (Type II, crude) or M1778 (Type III, partially purified); the two differ in bound sialic acid and in non-mucin content, so fix one in the batch record. Sigma M3895 bovine submaxillary mucin is offered as a porcine-free substitution by custom order. Defined glycans such as 2’-fucosyllactose can be supplied in a defined-glycan variant for specific substrate studies, but they present a single structure rather than the mixed O-glycan population of natural mucin. Any change of mucin source or grade is a change of formulation: revalidate growth and any glycan-dependent endpoint.
Q7. What is the expected colony morphology of Akkermansia muciniphila on GMM agar?
On the agar variant, expect small (approximately 0.5–1.5 mm), circular, convex, smooth, white-to-cream colonies after 48–72 h of anaerobic incubation at 37 °C. Colony size and timing are condition-dependent and will shift with inoculum, gas phase and plate age. A. muciniphila is a non-spore-forming, oval, Gram-negative-staining organism. A zone of mucin clearing around the colony is consistent with mucin degradation but is not unique to this species and is not an identification: confirm identity by 16S rRNA gene sequencing or an equivalent validated method. Haemolysis cannot be assessed on this medium, which contains no blood component.
Q8. How does GMM compare to mGAM for gut-microbiome recovery?
They are built for different jobs. This medium carries mucin, so it addresses mucin-degrading organisms such as Akkermansia muciniphila, Mediterraneibacter torques and M. gnavus, which a medium without a glycan source supports less well. Modified GAM has a richer digest and liver-extract base and is widely used for Bacteroides and Prevotella. For the broadest isolate collection, run several media in parallel rather than choosing one. For routine anaerobic culture where mucin-degraders are not the target, Modified GAM or YCFA Modified are the more economical choice. Relative recovery depends on the sample and conditions and is worth confirming on your own material.
Q9. Is the medium suitable for fermenter / bioreactor scale-up?
Yes, with process-specific qualification. Mucin-containing medium tends to foam under gas sparging, so an antifoam is usually required; select the agent and establish its working concentration for your vessel, and confirm it does not interfere with your analytical endpoints. Because the short-chain fatty acids and the hemin are part of the base, in-place sterilisation delivers both without a separate sterile addition; vitamin K1 is still dosed after the cycle, at 50 °C or below. Either route can be used for the acids where the process justifies it. Sterilisation cycle, gas transfer, mixing and pH control all change with vessel and scale and must be qualified rather than carried over from bench preparation. Technical support can advise on scale-up. Note that manufacturing a live biotherapeutic brings GMP, cell-bank and regulatory requirements that sit well beyond the specification of a research medium.
Q10. Is there a commercial ready-to-rehydrate GMM available from BD or Sigma?
No. As of the current literature search, GMM exists only as a published recipe (Goodman 2011 PNAS supplementary methods). The GMExpression product is the first commercially-validated ready-to-rehydrate GMM kit. This addresses a documented gap in the gut-culturomics-research market — labs currently must source ~12 individual ingredients (including hard-to-source porcine mucin and SCFA mix) and prepare from scratch each time.